scholarly journals Total En Bloc Thoracic and Lumbar Spondylectomy for Non-Small Cell Lung Cancer with Favorable Prognostic Indicators: Is It Merely Indicated for Solitary Spinal Metastasis?

2014 ◽  
Vol 56 (5) ◽  
pp. 431 ◽  
Author(s):  
Jong-Hwa Park ◽  
Seung-Jae Hyun ◽  
Ki-Jeong Kim ◽  
Tae-Ahn Jahng
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Spinal Metastasis ◽  
Small Cell ◽  
Prognostic Indicators ◽  
Small Cell Lung ◽  
En Bloc

scholarly journals Intramedullary thoracic spinal metastasis from small-cell lung cancer

2013 ◽  
Vol 79 (3-4) ◽  
Author(s):  
S. Katsenos ◽  
M. Nikolopoulou
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Spinal Metastasis ◽  
Small Cell ◽  
Mediastinal Lymphadenopathy ◽  
Small Cell Lung ◽  
Intramedullary Spinal Cord ◽  
Thoracic Spinal

Intramedullary thoracic spinal metastasis from small-cell lung cancer. S. Katsenos, M. Nikolopoulou. Lung cancer with intramedullary spinal cord metastasis (ISCM) is a rare event exhibiting dismal prognosis. In the present paper, we describe a 74-year-old male who developed bilateral leg weakness with associated backache and non-productive cough. Chest imaging evaluation demonstrated pronounced bilateral mediastinal lymphadenopathy and a nodular opacity in the right lower lobe. The patient was diagnosed with small cell lung cancer through bronchoscopic procedures. Magnetic resonance imaging of the spinal cord with contrast-enhancement revealed an intramedullary lesion consistent with metastasis at the T5-T6 level. Despite chemotherapy and thoracic spine radiotherapy, he eventually succumbed to the disease 3 months after diagnosis. A brief overview of the current literature is also provided laying emphasis on the therapeutic strategies of this unusual extrathoracic metastatic disease.

scholarly journals En bloc resection of non-small cell lung cancer invading the thoracic inlet and intervertebral foramina

2002 ◽  
Vol 123 (4) ◽  
pp. 676-685 ◽  
Author(s):  
Elie Fadel ◽  
Gilles Missenard ◽  
Alain Chapelier ◽  
Sacha Mussot ◽  
François Leroy-Ladurie ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
En Bloc Resection ◽  
Bloc Resection ◽  
Small Cell ◽  
Small Cell Lung ◽  
En Bloc ◽  
Thoracic Inlet ◽  
Intervertebral Foramina

scholarly journals Chromatin Remodeling Factors and BRM/BRG1 Expression as Prognostic Indicators in Non-Small Cell Lung Cancer

2004 ◽  
Vol 10 (13) ◽  
pp. 4314-4324 ◽  
Author(s):  
Junya Fukuoka ◽  
Takeshi Fujii ◽  
Joanna H. Shih ◽  
Tatiana Dracheva ◽  
Daoud Meerzaman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Chromatin Remodeling ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Prognostic Indicators ◽  
Small Cell Lung

scholarly journals Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy

Cancers ◽  
2021 ◽  
Vol 13 (17) ◽  
pp. 4280
Author(s):  
Beatriz Honrubia-Peris ◽  
Javier Garde-Noguera ◽  
Jose García-Sánchez ◽  
Nuria Piera-Molons ◽  
Antonio Llombart-Cussac ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Checkpoint Inhibitors ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Prognostic Indicators ◽  
Small Cell Lung ◽  
Treatment Scenario ◽  
Recent Advances

Numerous targeted therapies have been evaluated for the treatment of non-small cell lung cancer (NSCLC). To date, however, only a few agents have shown promising results. Recent advances in cancer immunotherapy, most notably immune checkpoint inhibitors (ICI), have transformed the treatment scenario for these patients. Although some patients respond well to ICIs, many patients do not benefit from ICIs, leading to disease progression and/or immune-related adverse events. New biomarkers capable of reliably predicting response to ICIs are urgently needed to improve patient selection. Currently available biomarkers—including programmed death protein 1 (PD-1) and its ligand (PD-L1), and tumor mutational burden (TMB)—have major limitations. At present, no well-validated, reliable biomarkers are available. Ideally, these biomarkers would be obtained through less invasive methods such as plasma determination or liquid biopsy. In the present review, we describe recent advances in the development of novel soluble biomarkers (e.g., circulating immune cells, TMB, circulating tumor cells, circulating tumor DNA, soluble factor PD-L1, tumor necrosis factor, etc.) for patients with NSCLC treated with ICIs. We also describe the potential use of these biomarkers as prognostic indicators of treatment response and toxicity.

Prognostic effect of a risk index model in postoperative non-small-cell lung cancer patients

2019 ◽  
Vol 15 (24) ◽  
pp. 2829-2840 ◽  
Author(s):  
Yun Li ◽  
Fenglong Bie ◽  
Yadong Wang ◽  
Wenting Wang ◽  
Jiajun Du
Keyword(s):  
Lung Cancer ◽  
Lymph Nodes ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Risk Index ◽  
Small Cell ◽  
Prognostic Indicators ◽  
Tumor Diameter ◽  
Small Cell Lung ◽  
Nsclc Patients

Aim: Predicting the prognostic outcome of a single case among postoperative non-small-cell lung cancer (NSCLC) patients is difficult. We created a precise prognostic model to assess the condition and prognosis of postoperative NSCLC patients. Methods: We combined eight prognostic indicators (age, prothrombin time, international normalized ratio, globulin, albumin-to-globulin ratio, tumor diameter, number of positive lymph nodes and number of dissected lymph nodes) to construct a new risk index (RI) model. Results: The best cut-off value was -1.86 (area under the curve: 0.719). The overall survival of postoperative NSCLC patients decreased as the RI increased (p < 0.001). Conclusion: This RI model can assist clinicians in screening high-risk groups and developing treatment and follow-up plans for postoperative NSCLC patients.

Sign in / Sign up

Export Citation Format

Share Document